Research Article
Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial
Table 3
The changes in concentrations of cell markers between days 0–5 and 0–14. Median (range).
| Marker median, range of healthy reference subjects, | APC baseline
| Placebo baseline
| -value | APC change 0–5 d
| Placebo change 0–5 d
| -value | APC change 0–14 d
| Placebo change 0–14 d
| -value |
| MoHLA-DR, % 95.0 (42–99),
| 54.0 (13–73) | 44.0 (26–75) | 0.599 | 10.0 (−21–30) | 1.00 (−50–22) | 0.173 | 13.0 (−18–37) | 31.0 (−29–65) | 0.152 | MoCD11b, RFU 126 (72–297),
| 284 (118–770) | 337 (136–673) | 0.953 | −91.5 (−290–123) | −76.5 (−348–114) | 0.877 | −35.0 (−301–445) | −15.0 (−497–150) | 0.349 | MoCD14, RFU 206 (74–379),
| 161 (87–306) | 186 (96.0–294) | 0.626 | −28.5 (−115–68) | −21.5 (−142–58) | 0.797 | −5.00 (−75–19) | −59.5 (−119–60) | 0.173 | PMNCD11b, RFU 130 (75–466),
| 324 (172–791) | 325 (161–519) | 0.861 | −50.5 (−426–236) | −66.0 (−219–164) | 0.918 | −37.0 (−215–242) | −74.0 (−346–89) | 0.173 | MoCD62L, RFU 118 (63–279),
| 217 (133–313) | 216 (87–343) | 0.892 | −65.5 (−208–15) | −68.0 (−226–18) | 0.979 | −95.5 (−212–11) | −109 (−212–8) | 0.481 | PMNCD62L, RFU 131 (85–193)
| 123 (40–239) | 164 (78–227) | 0.264 | −46.0 (−212–43) | −67.5 (−123–25) | 0.898 | −76.0 (−165–69) | −80.0 (−165–65) | 0.251 |
|
|
Mo: monocyte; PMN: neutrophil; RFU: relative fluorescence units.
|